Dr. Steve Yang is Vice President, and Head of Asia and Emerging Markets iMed at AstraZeneca. He is based in Shanghai, China and is responsible for developing, implementing and aligning the company’s R&D strategy for Asia and Emerging Markets. His main responsibilities include managing AstraZeneca’s research, early development and translational science efforts in China, ensuring the successful implementation of the company’s R&D strategy for Asia, and developing and executing the R&D strategy for Emerging Market countries outside Asia.
Prior to joining AstraZeneca, Dr. Yang was Vice President, Head of Asia R&D at Pfizer, where he was charged with establishing and expanding the company’s research partnership network with academic institutions, biotechnology firms and Contract Research Organizations across Asia Pacific. He was also responsible for delivering a portfolio of preclinical and clinical stage projects targeting unmet medical needs of emerging markets. Prior to his leadership position in Asia, Dr. Yang was Executive Director and head of the company’s global R&D strategic management group.
Before joining Pfizer, Dr. Yang held a number of positions at IntraBiotics Pharmaceuticals, a US-based biotech company and also worked for Strategic Decisions Group (SDG), a management consulting firm for Fortune 100 companies.
Dr Yang is the co-founder of the BayHelix Group, a non-profit professional organization of Chinese life science business leaders.
Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco, USA. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude in Biology from Michigan Technological University, USA.